Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$16.76 -11.1%	$16.34	$9.57 ▼ $29.86	$2.60B	0.93	1.58 million shs	3.01 million shs
BBIO BridgeBio Pharma	$46.51 -0.5%	$39.54	$21.72 ▼ $48.68	$8.88B	1.15	2.55 million shs	2.14 million shs
EVTCY Evotec	$4.24 +0.5%	$4.13	$14.22 ▼ $26.57	$1.40B	0.98	2,407 shs	24,819 shs
GBT Global Blood Therapeutics	$68.49	$68.47	$21.65 ▼ $73.02	$4.62B	0.45	2.07 million shs	74 shs
NKTR Nektar Therapeutics	$24.94 -6.5%	$15.75	$6.48 ▼ $37.38	$330.89M	0.94	521,697 shs	1.10 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.01%	-0.05%	+21.61%	+67.70%	-32.73%
BBIO BridgeBio Pharma	-0.76%	+1.02%	+16.65%	+38.00%	+66.99%
EVTCY Evotec	+0.48%	+1.69%	+2.18%	+17.22%	-11.72%
GBT Global Blood Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
NKTR Nektar Therapeutics	+10.48%	+6.25%	+205.50%	+179.38%	+22.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.8607 of 5 stars	3.4	2.0	0.0	3.4	3.7	1.7	0.0
BBIO BridgeBio Pharma	4.6238 of 5 stars	4.5	1.0	0.0	3.9	3.1	3.3	0.6
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	4.0678 of 5 stars	3.4	2.0	0.0	4.2	3.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	160.83% Upside
BBIO BridgeBio Pharma	3.00	Buy	$61.20	31.58% Upside
EVTCY Evotec	0.00	N/A	N/A	N/A
GBT Global Blood Therapeutics	0.00	N/A	N/A	N/A
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	254.18% Upside

Current Analyst Ratings Breakdown

Latest ARWR, GBT, EVTCY, BBIO, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $68.00
7/14/2025	BBIO BridgeBio Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
7/11/2025	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $67.00
7/9/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$60.00
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	651.99	N/A	N/A	$1.54 per share	10.88
BBIO BridgeBio Pharma	$221.90M	39.80	N/A	N/A	($7.71) per share	-6.03
EVTCY Evotec	$572.16M	2.45	$0.04 per share	105.53	$2.52 per share	1.68
GBT Global Blood Therapeutics	$194.75M	23.73	N/A	N/A	$3.05 per share	22.46
NKTR Nektar Therapeutics	$98.43M	3.14	N/A	N/A	$4.94 per share	5.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	22.17	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	10.34	∞	N/A	20.85%	16.02%	7.81%	N/A
GBT Global Blood Therapeutics	-$303.09M	-$5.01	N/A	N/A	N/A	-137.30%	-170.37%	-39.24%	N/A
NKTR Nektar Therapeutics	-$118.96M	-$9.60	N/A	N/A	N/A	-152.49%	-329.54%	-55.24%	8/6/2025 (Estimated)

Latest ARWR, GBT, EVTCY, BBIO, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	NKTR Nektar Therapeutics	-$2.58	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.50	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$2.70	-$3.30	-$0.60	-$0.24	$15.61 million	$10.46 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BBIO BridgeBio Pharma	N/A	4.57	4.54
EVTCY Evotec	0.53	2.57	2.50
GBT Global Blood Therapeutics	4.92	6.88	6.17
NKTR Nektar Therapeutics	N/A	3.24	3.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BBIO BridgeBio Pharma	99.85%
EVTCY Evotec	N/A
GBT Global Blood Therapeutics	N/A
NKTR Nektar Therapeutics	75.88%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BBIO BridgeBio Pharma	18.20%
EVTCY Evotec	N/A
GBT Global Blood Therapeutics	4.90%
NKTR Nektar Therapeutics	5.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
GBT Global Blood Therapeutics	457	67.48 million	64.17 million	Optionable
NKTR Nektar Therapeutics	220	12.41 million	11.76 million	Optionable

ARWR, GBT, EVTCY, BBIO, and NKTR Headlines

Recent News About These Companies

What is William Blair's Forecast for NKTR FY2025 Earnings?

July 18 at 3:01 AM | americanbankingnews.com

Research Analysts Set Expectations for NKTR FY2025 Earnings

July 16 at 6:46 AM | marketbeat.com

Wealth Enhancement Advisory Services LLC Purchases New Shares in Nektar Therapeutics (NASDAQ:NKTR)

July 12, 2025 | marketbeat.com

Q2 EPS Forecast for Nektar Therapeutics Lowered by Analyst

July 12, 2025 | americanbankingnews.com

Nektar Therapeutics (NASDAQ:NKTR) Receives $84.17 Consensus PT from Analysts

July 11, 2025 | americanbankingnews.com

Q2 EPS Estimate for Nektar Therapeutics Reduced by Analyst

July 10, 2025 | marketbeat.com

Nektar Therapeutics (NASDAQ:NKTR) Shares Sold by Peapod Lane Capital LLC

July 10, 2025 | marketbeat.com

49 Wealth Management LLC Buys New Holdings in Nektar Therapeutics (NASDAQ:NKTR)

July 9, 2025 | marketbeat.com

Nektar Therapeutics (NASDAQ:NKTR) Given New $85.00 Price Target at B. Riley

July 9, 2025 | americanbankingnews.com

B. Riley Raises Nektar Therapeutics (NASDAQ:NKTR) Price Target to $85.00

July 8, 2025 | marketbeat.com

Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of "Buy" from Brokerages

July 8, 2025 | marketbeat.com

Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin

July 6, 2025 | msn.com

Why Nektar Therapeutics Stock Dived by 3% Today

July 3, 2025 | fool.com

What is Zacks Research's Estimate for NKTR FY2025 Earnings?

July 3, 2025 | marketbeat.com

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

July 2, 2025 | prnewswire.com

Q2 EPS Estimate for Nektar Therapeutics Lowered by Analyst

July 2, 2025 | marketbeat.com

Nektar Therapeutics Announces Public Offering of Shares

July 1, 2025 | tipranks.com

Nektar Therapeutics stock dips after pricing $100M stock offering

July 1, 2025 | seekingalpha.com

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

July 1, 2025 | prnewswire.com

Nektar Therapeutics launches proposed public offering

June 30, 2025 | msn.com

Nektar Therapeutics stock falls after announcing public offering

June 30, 2025 | in.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

ARWR, GBT, EVTCY, BBIO, and NKTR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.76 -2.09 (-11.09%)

Closing price 04:00 PM Eastern

Extended Trading

$16.86 +0.10 (+0.60%)

As of 07:54 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BridgeBio Pharma NASDAQ:BBIO

$46.51 -0.23 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$47.18 +0.68 (+1.45%)

As of 07:39 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Evotec OTCMKTS:EVTCY

$4.24 +0.02 (+0.47%)

As of 07/17/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Nektar Therapeutics NASDAQ:NKTR

$24.94 -1.73 (-6.49%)

Closing price 04:00 PM Eastern

Extended Trading

$24.62 -0.33 (-1.30%)

As of 07:59 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time